3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
560
Neoplasms
504
Carcinoma, Non-Small-Cell Lung
421
Prostatic Neoplasms
331
Colorectal Neoplasms
315
Lung Neoplasms
284
Neoplasm Metastasis
238
Leukemia, Myeloid, Acute
222
Ovarian Neoplasms
206
Pancreatic Neoplasms
196
Multiple Myeloma
186
Squamous Cell Carcinoma of Head and Neck
141
Stomach Neoplasms
140
Recurrence
140
Brain Neoplasms
139
Melanoma
134
Carcinoma, Hepatocellular
132
Endometrial Neoplasms
128
Glioblastoma
126
Precursor Cell Lymphoblastic Leukemia-Lymphoma
117
Triple Negative Breast Neoplasms
116
Hematologic Neoplasms
104
Head and Neck Neoplasms
103
Carcinoma, Renal Cell
102
Urinary Bladder Neoplasms
99
Lymphoma
99
Sarcoma
96
Glioma
96
Esophageal Neoplasms
92
Uterine Cervical Neoplasms
88
Interventions
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Limited Stage Small Cell Lung Cancer
×
90 days
×
Clear all
NCT06773910
2026-04-22
TIGOS-LS
SCRI Development Innovations, LLC
Phase 2
Recruiting
250 enrolled